Algernon Pharmaceuticals Inc (CSE:AGN) (OTCB:BTHCF) (FRA:AGW) announced that it has reached 25% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil).
“I am very pleased to report that we have reached 25% enrollment in the study,” said CEO Christopher J. Moreau in a statement.
“While our COVID-19 clinical trial program has received a great deal of attention, IPF and chronic cough are very serious conditions as well, and our team is working hard to make sure our clinical program of investigating Ifenprodil as a possible treatment continues to move forward on schedule.”
Vancouver-based Algernon said the purpose of the open-label, proof-of-concept Phase 2 human trial of 20 patients is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough.
There are five sites in total participating in the study with three located in Australia and two in New Zealand.
Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of (IPF). In addition, Ifenprodil significantly reduced both cough frequency and onset in a guinea pig acute cough model.
The drug is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signaling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.
Contact the author: firstname.lastname@example.org
Follow him on Twitter @PatrickMGraham